Journal
CURRENT COMPUTER-AIDED DRUG DESIGN
Volume 4, Issue 1, Pages 46-53Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/157340908783769265
Keywords
PET; SPECT; radioligands; tumor imaging; tumor biomarkers; drug development
Funding
- NCI NIH HHS [P50 CA093990, P01 CA085878-06, P50 CA093990-07A1, U24 CA083099, P01 CA085878, U24 CA083099-10, R24 CA083099] Funding Source: Medline
Ask authors/readers for more resources
Spiraling drug developmental costs and lengthy time-to-market introduction are two critical challenges facing the pharmaceutical industry. The clinical trials success rate for oncology drugs is reported to be 5% as compared to other therapeutic categories (11%) with most failures often encountered late in the clinical development process. PET and SPECT nuclear imaging technologies could play an important role in facilitating the drug development process improving the speed, efficiency and cost of drug development. This review will focus on recent studies of PET and SPECT radioligands in oncology and their application in the investigation of tumor biology. The use of clinically-validated radioligands as imaging-based biomarkers in oncology could significantly impact new cancer therapeutic development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
